A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung

Anaplastic lymphoma kinase (ALK) gene rearrangement is an essential driver mutation identified in approximately 5% of non-small cell lung cancers (NSCLCs). The results of clinical trials have demonstrated the impressive efficacy of ALK tyrosine kinase inhibitors (ALK-TKIs). Besides the classic EML4-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Xiaojing, He, Qianru, Xing, Xiaodan, Yang, Yanming, Ma, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933637/
https://www.ncbi.nlm.nih.gov/pubmed/35313528
http://dx.doi.org/10.2147/OTT.S347200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933637/
https://www.ncbi.nlm.nih.gov/pubmed/35313528
http://dx.doi.org/10.2147/OTT.S347200

Ejemplares similares